



# SUDARSHAN PHARMA INDUSTRIES LIMITED



Corporate Identification Number: U51496MH2008PLC184997

Our Company was originally incorporated on July 23, 2008 as a Private Limited Company as "Sudarshan Speciality Chemsolve Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from "Sudarshan Specialty Chemsolve Private Limited" to "Sudarshan Pharma Industries Private Limited" under the Companies Act, 2013 pursuant to a special resolution passed by our shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of our Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016. Our Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of our Company was changed to "Sudarshan Pharma Industries Limited" and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai. The Corporate Identification Number of our Company is U51496MH2008PLC184997.

Registered office: 301,3rd Floor, Aura Biplax, Above Kalyan Jewellers S. V. Road, Borivali (West) Mumbai City Maharashtra 400092 India.

Contact Person: Mr. Hemal Vasantrai Mehta, Managing Director

Email Id: compliance@sudarshanpharma.com | Tel No: 022- 42221111

**PROMOTERS OF OUR COMPANY: Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta**

## THE ISSUE

**PUBLIC ISSUE OF UPTO 68,62,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SUDARSHAN PHARMA INDUSTRIES LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [●] LAKHS ("THE ISSUE") OF WHICH 3,44,000 EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF Upto 65,18,400 EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.52% AND 27.09% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. PRICE BAND: ₹71.00 TO ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10/- EACH AND THE ISSUE PRICE IS 7.1 TO 7.3 TIMES OF THE FACE VALUE AT THE LOWER PRICE BAND AND THE UPPER PRICE BAND RESPECTIVELY. BID CAN BE MADE FOR MINIMUM OF 1600 EQUITY SHARES AND THE MULTIPLES OF 1600 EQUITY SHARES THEREAFTER.**

**ANCHOR  
PORTION ISSUE**

**OPENS / CLOSSES ON: WEDNESDAY, MARCH 08, 2023**

**ISSUE**

**OPENS ON: THURSDAY, MARCH 09, 2023  
CLOSSES ON: TUESDAY, MARCH 14, 2023**

## CORRIGENDUM TO THE RED HERRING PROSPECTUS DATED FEBRUARY 27, 2023

### ATTENTION

The Corrigendum is with reference to the Red Herring Prospectus dated February 27, 2023 filed by Sudarshan Pharma Industries Limited in relation to the Issue with Registrar of Companies, Mumbai on February 27, 2023 and submitted with BSE Limited ("BSE") (SME Exchange).

Attention of Investors is drawn

- To Percentage of Issue Size available for allocation to Non-Institutional Investors & Retail Individual Investors wherever mentioned in Red Herring Prospectus of the Company

Particulars of the Issue	Non-Institutional Investors		Retail Individual Investors	
	Old	New	Old	New
Percentage of Issue Size available for allocation	Not less than 15% of the Net Issue less allocation to QIB Bidders and RIBs will be available for allocation	Not less than 40% of the Net Issue less allocation to QIB Bidders and RIBs will be available for allocation	Not less than 35% of the Net Issue less allocation to QIBs and Non-Institutional Bidders will be available for allocation	Not less than 40% of the Net Issue less allocation to QIBs and Non-Institutional Bidders will be available for allocation

- On Page No. 70, Wherein it is stated that Public Shareholders as "64", it will read as "59" and Total Shareholders as "73", it will read as "68"
- On Page No. 90, wherein it is stated as "We have 73 (Seventy-Three) Shareholders as on the date of this Red Herring Prospectus", it will read as "We have 68 (Sixty-Eight) Shareholders as on the date of this Red Herring Prospectus".
- On Page No. 91, wherein amongst the No. of Equity Shares locked in by Mr. Hemal Vasantrai Mehta are stated 10,14,311 Equity Shares will read as 10,30,199 Equity Shares and Total shall read as 23,66,220 Equity Shares instead of 23,50,332 Equity Shares.
- On Page No. 79, the names of shareholders Dhaval Bharat Siriya, Bharat Suryakant Siriya, Hetal Vivek Siriya and Rekha Bharat Siriya shall be read as Sangeeta Jain.
- On Page No. 77, the names of shareholders Jyoti Jignesh Vastani and Jignesh Dalsukhrai Vastani (HUF) shall read as Jignesh Dalsukhrai Vastani.

The above to be read in conjunction with the Red Herring Prospectus. The information in this CORRIGENDUM supplements the Red Herring Prospectus and updates the information in the Red Herring Prospectus as applicable. Please note that changes pursuant to this CORRIGENDUM will appropriately mentioned in the Prospectus and will be filed with the Registrar of Companies (RoC). All capitalized term used in the notice shall, unless the context otherwise requires, has the meaning ascribed in the Red Herring Prospectus.

For SUDARSHAN PHARMA INDUSTRIES LIMITED

Sd/-

Hemal Vasantrai Mehta

Managing Director

DIN: 02211121

Place: Mumbai

Date: March 03, 2023